Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P17706
UPID:
PTN2_HUMAN
Alternative names:
T-cell protein-tyrosine phosphatase
Alternative UPACC:
P17706; A8K955; A8MXU3; K7ENG3; Q96AU5; Q96HR2
Background:
Tyrosine-protein phosphatase non-receptor type 2, also known as T-cell protein-tyrosine phosphatase, plays a pivotal role in dephosphorylating receptor and non-receptor protein tyrosine kinases. It is crucial in regulating signaling pathways that influence cell proliferation, differentiation, immune system development, and glucose homeostasis. Its activity affects various cytokine-mediated signaling, impacting inflammatory responses and T-cell activation.
Therapeutic significance:
Understanding the role of Tyrosine-protein phosphatase non-receptor type 2 could open doors to potential therapeutic strategies. Its involvement in key biological processes and signaling pathways suggests its potential as a target in treating diseases related to immune system dysfunction, metabolic disorders, and certain cancers.